Cardiologists at a tertiary care center are analyzing final data from a 5-year pharmaceuti… — USMLE Step 2 CK

Cardiologists at a tertiary care center are analyzing final data from a 5-year pharmaceutical trial. The trial compared a next-generation platelet inhibitor to standard aspirin therapy for preventing recurrent ischemic events in adults with a history of acute coronary syndrome. Initial calculations show an overall relative risk (RR) of $0.82$ ( $95\% \text{ CI}: 0.75-0.91$ ) for the new medication group compared to the aspirin group. However, when the patient data is separated according to hepatic cytochrome P450 polymorphism status, distinct patterns emerge. Patients with the wild-type polymorphism have an RR of $0.58$ ( $95\% \text{ CI}: 0.49-0.68$ ), whereas patients with the loss-of-function polymorphism have an RR of $1.04$ ( $95\% \text{ CI}: 0.91-1.19$ ). Based on these statistical results, which of the following is the most accurate interpretation of the polymorphism's role?

The genetic polymorphism biologically alters the clinical efficacy of the next-generation platelet inhibitor.Cevap
B
An unequal baseline distribution of the genetic polymorphism between the study arms skewed the initial combined results.
C
Differential loss to follow-up between the polymorphism groups artificially created the divergent risk estimates.
D
The sample size within the separated genetic groups was statistically insufficient to detect a uniform therapeutic benefit.
E
Knowledge of the genetic status inadvertently influenced how the adjudicating committee diagnosed recurrent ischemic events.

Cevap

The genetic polymorphism biologically alters the clinical efficacy of the next-generation platelet inhibitor.

The correct answer accurately identifies a biological interaction. In epidemiological terms, when an association between an exposure (the new drug) and an outcome (ischemic events) differs significantly across strata of a third variable (genotype), that third variable is biologically altering the efficacy of the intervention. The mathematical proof of this is the significant difference between the stratum-specific relative risks (

0.58

1.04

) and the fact that their

95\%

confidence intervals do not overlap.

Adım Adım Çözüm

Analyze the unadjusted (crude) relative risk.

The unadjusted RR is

0.82

, suggesting an overall

18\%

reduction in recurrent ischemic events with the new medication.

Establishing the baseline overall finding is required before evaluating the impact of stratification.

Evaluate the stratum-specific relative risks.

The wild-type stratum has an RR of

0.58

(significant protection), while the loss-of-function stratum has an RR of

1.04

(no protection).

Comparing the strata reveals how the third variable (genotype) impacts the primary association.

Determine the epidemiological phenomenon based on the strata comparison.

Because the two stratified relative risks are significantly different from one another (their confidence intervals do not overlap), the third variable is causing a true biological interaction.

When a third variable changes the magnitude or direction of an exposure's effect on an outcome, it represents a biological interaction, distinguishing it from situations where a third variable merely distorts the data.

Anahtar Kavram

Identifying biological interaction based on divergent stratified risk estimates.

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru